Phase III Clinical Trial "Platelet Oriented Inhibition in New Tia" - Drug: Plavix

Sponsor: Sanofi-Aventis Group

Location(s): United States


The purpose of this study is to determine the safety and effectiveness of the combination of low-dose aspirin and a medication called clopidogrel (also known by the brand name Plavix®) in reducing the risk of stroke, heart attacks and other complications in patients who have just had a TIA or minor ischemic stroke.